Detailed Information
Cited 1 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Management of fibroblast growth factor receptor inhibitor (FGFRi) treatment-emergent adverse events (TEAEs) of interest in patients (Pts) with locally advanced or metastatic urothelial carcinoma (mUC).
- Authors
- Siefker-Radtke, AO[Siefker-Radtke, Arlene O.]; Necchi, A[Necchi, Andrea]; Park, SH[Park, Se Hoon]; Garcia-Donas, J[Garcia-Donas, Jesus]; Huddart, RA[Huddart, Robert A.]; Burgess, EF[Burgess, Earle F.]; Fleming, MT[Fleming, Mark T.]; Rezazadeh, A[Rezazadeh, Arash]; Mellado, B[Mellado, Begona]; Varlamov, S[Varlamov, Sergei]; Joshi, M[Joshi, Monika]; Duran, I[Duran, Ignacio]; Tagawa, ST[Tagawa, Scott T.]; Zakharia, Y[Zakharia, Yousef]; Qi, KQ[Qi Keqin]; Monga, M[Monga, Manish]; Sondhi, M[Sondhi, Manu]; OHagan, A[OHagan, Anne]; Loriot, Y[Loriot, Yohann]
- Issue Date
- 20-Feb-2021
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.39, no.6
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 39
- Number
- 6
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.